/C O R R E C T I O N -- Optimer Pharmaceuticals, Inc./
In the news release, Optimer Pharmaceuticals (OPTR) to Host Conference Call and Webcast to Discuss First Quarter 2012 Financial Results, issued 25-Apr-2012 by Optimer Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that Optimer will report first quarter 2012 financial results after the NASDAQ Global Market closes on May 10, rather than May 8, as originally issued. The complete, corrected release follows:Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2012 Financial Results
SAN DIEGO, April 25, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced it will report first quarter 2012 financial results after the NASDAQ Global Market closes on May 10. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results and highlights for the first quarter as well as provide a corporate update.
The conference call may be accessed by dialing (877) 280-7280 for domestic callers and +1 (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Financial Results Call." The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in the European Union under the trade name DIFICLIR". The company is seeking marketing authorization for fidaxomicin in Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
Jason I. Spark, Senior Vice President
SOURCE Optimer Pharmaceuticals, Inc.